image credit- ACN Newswire
VectorBuilder Biotechnology (Guangzhou) Co., a top gene delivery startup, recently announced the completion of its Series C round with CNY410 million, co-led by Legend Capital. The proceeds will facilitate VectorBuilder in continuously promoting the upgrading and capacity expansion of the gene delivery R&D and production technology platform, further accelerate the global business presence, and boost the R&D of life sciences and genetic medicines.
The company provides services such as scientific research and clinical carrier CRO, gene-drug CDMO and gene delivery IP out-licensing, covering the entire field of life science and gene medicine.
VectorBuilder has provided more than 1.2 million gene delivery solutions to more than 4,000 scientific research institutes and pharmaceutical companies worldwide, and its gene-drug CRO and CDMO projects are spread all over North America, Europe, Japan and South Korea.
Dr Bruce Lahn, Founder and Chief Scientist of VectorBuilder, said: "We jointly launched the construction of a 45,000-square-meter gene delivery R&D and production base with Guangzhou Development District Investment Group in April 2022. We hope to take this financing round as an opportunity to further accelerate the comprehensive upgrade and optimization of the technology platform and promote the expansion of production capacity and global presence."
